Using a virus to target and kill triple-negative breast cancer cells
Development of Oncolytic Reovirus for Triple-Negative Breast Cancer
This study is looking at how a virus called reovirus can help fight triple-negative breast cancer by killing the cancer cells, and it aims to find ways to make this treatment even better by combining the virus with certain cancer drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10996072 on NIH RePORTER |
What this research studies
This research investigates how a specific virus, known as reovirus, can infect and kill triple-negative breast cancer (TNBC) cells. The team aims to understand the factors that enhance the virus's ability to target these cancer cells and to identify small molecules that can improve the effectiveness of the virus in killing cancer. By combining reovirus with certain cancer drugs, they hope to create a more effective treatment strategy for patients with TNBC. The research involves laboratory experiments to explore the mechanisms of cell death and the interactions between the virus and cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who do not have cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment option for patients with triple-negative breast cancer, potentially improving survival rates.
How similar studies have performed: Other studies have shown promise in using oncolytic viruses for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Lowen, Anice C — Emory University
- Study coordinator: Lowen, Anice C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.